Image of the Month in the European Journal of Nuclear Medicine: result obtained using one of Pars Isotope’s research radiopharmaceuticals

The radiopharmaceutical Lu-177-FAP-2286 was used in combination with chemotherapy to treat a patient with metastatic breast cancer in the lymph nodes, sternum and bones, with amazing results.

Pars Isotope’s research on various FAP peptides is ongoing and all stages of its trials are progressing. After going through all the stages of FAP-2286 labeled with Gallium-68/Lutetium-177 for the diagnosis and treatment of tumors that respond to this peptide and have a wide range, we are completing the documentation and adding it to our product portfolio.

A 42-year-old patient with primary breast cancer that had spread to the lymph nodes, sternum and bones received regular doses of the radiopharmaceutical Lu-177-FAP-2286 at six-week intervals, along with chemotherapy drugs.

 Receiving the radiopharmaceutical enhanced the effectiveness of the chemotherapy drugs, and the synergy between the two treatments not only destroyed the tumor metastases, but also completely cured the primary tumor.

One month after the last dose of Lu-177-FAP-2286 radiopharmaceutical, the patient underwent a Ga-68-FAP-2286 and FDG PET scan. The results of the scan showed that there were no signs of cancer cells in the pre-treatment areas and the patient was completely cured. The result of this work was selected as the image of the month in the European Journal of Nuclear Medicine.

3 nuclear medicine and radiopharmaceutical journals in the world have published the results of this research in the form of 4 articles, and the extraction of the results of this research continues in Pars Isotope.

By producing new products and increasing the quality of other products, Pars Isotope is now one of the top radiopharmaceutical companies in the world.